PUBLISHER: Lucintel | PRODUCT CODE: 1556601
PUBLISHER: Lucintel | PRODUCT CODE: 1556601
Radioimmunoassay (RIA) Trends and Forecast
The future of the global radioimmunoassay (RIA) market looks promising with opportunities in the hospital, pharmaceutical, academic, and clinical diagnostic laboratory markets. The global radioimmunoassay (RIA) market is expected to grow with a CAGR of 3.2% from 2024 to 2030. The major drivers for this market are increasing rates of cancer incidence, growing need for automation in healthcare, and rising advancement in medical research.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Radioimmunoassay (RIA) by Segment
The study includes a forecast for the global radioimmunoassay (RIA) by type, application, end use, and region.
List of Radioimmunoassay (RIA) Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radioimmunoassay (RIA) companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radioimmunoassay (RIA) companies profiled in this report include-
Radioimmunoassay (RIA) Market Insights
Lucintel forecasts that reagent & kit is expected to witness higher growth over the forecast period.
Within this market, clinical diagnostic laboratory is expected to witness the highest growth due to substantial usage of radioimmunoassay in this facility given to their ability to analyze a broad variety of analytes in biological samples with high throughput, high sensitivity, and specificity.
North America will remain the largest region over the forecast period due to availability of favorable reimbursement policy and existence of robust healthcare system in the region.
Features of the Global Radioimmunoassay (RIA) Market
Market Size Estimates: Radioimmunoassay (RIA) market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Radioimmunoassay (RIA) market size by type, application, end use, and region in terms of value ($B).
Regional Analysis: Radioimmunoassay (RIA) market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, end uses, and regions for the radioimmunoassay (RIA) market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radioimmunoassay (RIA) market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q1. What is the growth forecast for radioimmunoassay (RIA) market?
Answer: The global radioimmunoassay (RIA) market is expected to grow with a CAGR of 3.2% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the radioimmunoassay (RIA) market?
Answer: The major drivers for this market are increasing rates of cancer incidence, growing need for automation in healthcare, and rising advancement in medical research.
Q3. What are the major segments for radioimmunoassay (RIA) market?
Answer: The future of the radioimmunoassay (RIA) market looks promising with opportunities in the hospital, pharmaceutical, academic, and clinical diagnostic laboratory markets.
Q4. Who are the key radioimmunoassay (RIA) market companies?
Answer: Some of the key radioimmunoassay (RIA) companies are as follows:
Q5. Which radioimmunoassay (RIA) market segment will be the largest in future?
Answer: Lucintel forecasts that reagent & kit is expected to witness higher growth over the forecast period.
Q6. In radioimmunoassay (RIA) market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to availability of favorable reimbursement policy and existence of robust healthcare system in the region.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.